RA Capital Management is a Boston-based investment firm focused on healthcare, life sciences, and planetary health, investing in public and private companies across stages from seed to late-stage financings. The firm emphasizes evidence-based, science-led investing guided by internal research capabilities, including TechAtlas. It operates Raven, a biomedical innovation incubator that supports entrepreneurs and developers, and pursues value creation through collaborative partnerships, often co-investing and taking board positions. With a multidisciplinary, data-driven approach, RA Capital seeks to back management teams from inception through commercialization and beyond, aiming to improve patient outcomes and advance medical innovation.

SOSV is a global venture capital firm that provides early-stage and seed investments alongside structured accelerator programs and deeply resourced facilities to accelerate product development. Focused on deep tech, human and planetary health, and cross-border software, SOSV backs startups from pre-seed onward and runs programs that accelerate technical development, regulatory strategy, and fundraising. The firm maintains labs and engineering spaces with specialist staff in multiple regions, including the United States and Asia, to support portfolio companies in biosafety, chemistry, mechatronics, analytics, and electrical engineering. Programs such as HAX and other live events offer founders access to prototyping, testing, and investor networks. Annually, SOSV makes around sixty pre-seed investments (up to roughly $550k each) and participates in numerous follow-on rounds, leveraging a global portfolio and extensive co-investor network to help deeply technical startups scale and reach markets.

OrbiMed is a global healthcare-focused investment firm founded in 1989 and headquartered in New York. It manages assets across public and private markets and pursues opportunities across the healthcare spectrum, including biopharmaceuticals, medical devices, diagnostics, digital health, and health services. The firm invests in startups, growth-stage companies, and established entities, leveraging scientific and medical expertise to support development and commercialization. It also offers financing solutions such as structured debt and royalty monetization for intellectual property and medical diagnostics.

Founded in 1985, The Invus Group is a global private equity firm that partners with entrepreneurs, founders and management teams across the company lifecycle. Blending a family-office approach with multi-strategy investing, it supports transformative growth in sectors including consumer products and services, technology, life sciences, software, agtech, industrials, education and medical devices. The firm pursues long-term value creation through strategic insight, capital and execution, investing in companies from early stages to mature businesses and providing both lead investments and co-investments in private transactions worldwide. It maintains a global footprint with offices in New York, London, Paris and Hong Kong and has a flexible structure designed to align incentives with partners over time.

ARCH Venture Partners is a Chicago-based venture capital firm founded in 1986 that concentrates on science-driven investments in life sciences, biotechnology, medical technologies, and related fields. The firm backs companies at multiple stages, often co-founded with scientists and entrepreneurs, aiming to translate academic research and national laboratory innovations into therapies, diagnostics, and other breakthrough technologies. ARCH emphasizes deep involvement, technical expertise, and a wide network to support founders from early development through later rounds, acting as a partner rather than a passive investor. With a focus on markets centered in the United States and North America, the firm frequently funds startups emerging from universities and research institutions and has built a track record of helping scientists bring innovations to market.

Casdin Capital is a New York-based investment firm focused on the life sciences and healthcare sectors. It targets biotechnology, genomics, precision medicine, oncology, digital health, and related technologies, applying data-driven, research-intensive analysis to identify disruptive opportunities in the field. The firm makes private investments across stages and seeks to partner with companies developing innovative therapies, diagnostics, and tools that advance healthcare. Founded in 2012 by Eli Casdin, Casdin Capital operates as a registered investment adviser and emphasizes a long-term, fundamental approach to identifying paradigm shifts in life sciences.

European Innovation Council is a European Union initiative established in 2018 to support deep-technology innovation and help startups, researchers, and small companies scale. It offers funding opportunities and business acceleration services, and engages in co-investment with private investors in early-stage ventures with ESG impact. The EIC emphasizes female entrepreneurship through programs such as Women TechEU and related awards, and provides resources to promote knowledge sharing and community building. Based in Brussels, it pursues a European-wide mandate to strengthen Europe's position in the global deep-tech ecosystem.

Sofinnova Partners is an independent venture capital firm based in Paris, France, specializing in life sciences investments from seed to later stages. It backs start-ups, early-stage companies, corporate spin-offs, and occasionally turnarounds, with a focus on biopharmaceuticals, biotechnology, medical devices, industrial biotechnology and related healthcare sectors. The firm typically takes a lead or cornerstone investor role, often chairs or sits on boards, and supports portfolio companies from formation through growth toward exit. Founded in 1972, it has a long track record in partnering with entrepreneurs and managing substantial assets dedicated to life sciences investing.

Atlas Venture is a Cambridge, Massachusetts-based venture capital firm that specializes in building and funding early-stage biotechnology and life sciences companies, as well as technology ventures. Founded in 1980, it uses a seed-led venture creation approach to translate scientific discoveries into scalable medicines and biotech businesses, often acting as a lead investor and seeking board representation for portfolio companies.

Deerfield Management is a New York City-based healthcare investment and information platform that advances healthcare through flexible funding models, AI-driven intelligence, and philanthropy. It connects people, capital, ideas, and technology across the healthcare ecosystem by investing in and building companies, powered by Deerfield Discovery and Development (3DC), a company-building R&D engine where bench scientists and industry veterans collaborate, and Cure, a New York City hub housing portfolio companies and in-building labs with advanced equipment. It has partnered with Blue Cross Blue Shield of North Carolina to build Alo, a platform enabling independent physicians to manage the business of medicine. Its Intelligence offering leverages AI, data, and market research to drive healthcare technology and innovation, while the Deerfield Foundation funds philanthropic initiatives in education, healthcare access, and health outcomes. The firm pursues strategic partnerships and external collaborations to accelerate progress across biotechnology, pharmaceuticals, diagnostics, devices, and services.

Khosla Ventures is a California-based venture capital firm founded in 2004 that provides capital and strategic support to technology-driven startups across early- to late-stage cycles. It pursues opportunities in AI, digital health, healthcare technologies, sustainability, fintech, consumer and enterprise technology, and other frontier areas, focusing on innovative business models and world-class teams. The firm emphasizes a contrarian, long-term approach and seeks to help entrepreneurs address meaningful societal and economic challenges through science, technology, and design.

New Enterprise Associates is a United States-based venture capital firm founded in 1977 and headquartered in Menlo Park, California. It invests in technology and healthcare companies across multiple stages, from seed to growth and IPO, and provides strategic support in product development and market expansion. The firm targets sectors including software, AI, consumer technology, digital health, life sciences, and energy technology, and pursues opportunities worldwide. NEA emphasizes long-term partnerships with founders, drawing on domain expertise and a broad network to help portfolio companies scale. It maintains a diverse portfolio across the United States, Asia and other regions, reflecting a global approach to venture investing.

Forbion is a venture capital firm based in Naarden, Netherlands, with over twenty years of experience investing in biotech and life sciences. It focuses on human health, planetary health, and the bioeconomy, supporting early-stage and growth investments across Europe and North America in drug development, MedTech, and sustainable solutions. Its portfolio includes gene therapy and other innovative therapies for rare diseases. Forbion manages funds totaling about €5 billion in committed capital across multiple vehicles and prioritizes ESG principles in its investment approach, seeking to accelerate scientific advances and drive long-term value for portfolio companies.

Versant Ventures is a healthcare-focused venture capital firm founded in 1999 and headquartered in San Francisco. It invests across the healthcare sector, including life sciences, biotechnology, pharmaceuticals, and medical devices, at all stages with an emphasis on discovery and development of novel therapeutics. The firm operates globally with offices in Canada, the United States, and Europe, delivering hands-on support to portfolio companies through in-house scientific and operating expertise. Versant pursues collaborative partnerships with entrepreneurs to translate research into clinical and commercial success and has a track record of portfolio companies achieving successful acquisitions or IPOs. The firm is registered as an investment adviser.

Flagship Pioneering is a Cambridge, Massachusetts-based venture builder that conceives, creates, resources, and scales first-in-category companies in health, biotechnology, and sustainability. It turns early scientific breakthroughs into durable platforms and enterprises by combining scientific discovery with entrepreneurial leadership and capital management, pursuing transformative outcomes through an evolutionary approach. With more than 25 years of experience, Flagship builds ecosystems that connect science, startups, and collaboration across partners. Notable portfolio companies include Moderna, Tessera Therapeutics, Generate Biomedicines, Inari Agriculture, Quotient Therapeutics, Lila Sciences, and Serif Biomedicines, reflecting a focus on pioneering medicines, intelligence, and preemptive health. The firm collaborates with major partners such as Genentech, Pfizer, GSK, Novo Nordisk, and Montai Therapeutics and engages in technology partnerships like AWS to accelerate discovery. Flagship emphasizes global health impact and disruptive science, fostering programs and opportunities through initiatives such as the Flagship Fellowship.

Leaps by Bayer is the corporate venture capital arm of Bayer, founded in 2015 and based in Leverkusen, Germany. It invests in paradigm-shifting advances in the life sciences, focusing on biotechnology, agriculture, and scientific breakthroughs to accelerate transformative biotechnologies. The unit seeks innovations that could redefine healthcare by moving beyond treating symptoms toward cures or prevention and contribute to sustainable agriculture, aiming to deliver meaningful, broad-scale impact for society.

Vivo Capital is a global healthcare investment firm founded in 1996 and headquartered in Palo Alto, California, with offices in Asia. The firm manages approximately $5.8 billion in assets under management and has invested in over 290 public and private healthcare companies worldwide. Its multi‑fund platform covers growth equity, private equity including buyouts, venture capital, and public equity, and it makes investments across biotechnology, pharmaceuticals, medical devices, and healthcare services in major markets, with a focus on the United States and China. The team comprises about 50 professionals including physicians, scientists, entrepreneurs, operating executives, and industry experts who collaborate to build and grow high‑quality healthcare companies.

5AM Ventures is a San Francisco-based venture capital firm founded in 2002 by John Diekman and Andrew Schwab. It focuses on seed- and early-stage investments in life sciences and healthcare, including biopharmaceuticals, biotechnology, drug delivery, medical technology, and research instruments, with additional interest in digital health and health technology. The firm maintains a Boston office and targets opportunities across the United States and North America, partnering with academics and entrepreneurs to build next-generation life science companies. It also operates an internal initiative called 4:59 to identify, incubate, and fund breakthrough science.

Logos Capital is a San Francisco-based biotechnology investment firm founded in 2019 that combines in-house data analytics with scientific and clinical expertise to identify transformative therapies. The firm uses a disciplined, data-driven approach and a proprietary Logos Analytics platform to model clinical data, assess likelihood of clinical success, and support comprehensive underwriting, ongoing event tracking, and proactive risk management. Its team spans medical, scientific, and business disciplines, with the aim of delivering long-term returns through investments in therapies that have the potential to improve patient outcomes and redefine standards of care.

Vida Ventures is a Boston-based life sciences investment firm and venture capital investor focused on turning biomedical innovations into therapies. Founded in 2017 by scientists, physicians, entrepreneurs and investors, the firm operates bi-coastally and backs companies across the United States, Canada and Europe, with activities spanning oncology, immunology, neuroscience and rare diseases. Vida Ventures collaborates with established pharmaceutical companies to accelerate drug development and supports portfolio companies through meaningful financings, emphasizing patient-centric, entrepreneurial and collaborative approaches to translating science into patient impact.

Samsara BioCapital is a Palo Alto-based venture capital firm focused on biotechnology and transformative therapeutics. Founded in 2016, it invests in the healthcare sector across the United States and operates as an investment adviser. The firm collaborates with scientists, physicians, drug developers, and business leaders to support ambitious biotechnology companies and advance a portfolio of therapeutic projects aimed at delivering innovative medicines to patients.

The Column Group is a San Francisco-based venture capital firm focused on biotechnology and life sciences, including oncology and drug discovery. It supports startups from early discovery through commercialization, taking a long-term view to build companies around robust scientific platforms and multiple product opportunities rather than short-term exits. The firm emphasizes deep scientific expertise, strong teams, collaboration, and mentorship, exemplified by the Swanson Fellowship. It manages more than $4 billion in assets and has backed about 55 biotech companies, generating substantial returns and multiple exits. The organization operates a portfolio of funds to support its activities from discovery to market and maintains an edge-to-edge, long-term investment approach.

BioVenture, established in September 2013, specializes in early-stage venture capital investments in the field of life sciences, focusing on biotechnology, drug discovery, medical devices, and healthcare services companies. With a fund size of 540 million yuan, BioVenture provides capital and post-investment support to innovative companies with high growth potential. Backed by Suzhou Industrial Park and BioBay, BioVenture aims to become one of China's most successful medical and pharmaceutical venture funds by leveraging its industry expertise and resources. The team at BioVenture consists of senior investment professionals with deep knowledge of domestic and foreign markets, aiming to help companies grow rapidly and achieve greater success while delivering considerable returns to fund investors. Through joint venture development cooperation, BioVenture seeks to drive innovation and growth in the medical and pharmaceutical industry.

Lux Capital is a venture capital firm focused on investing in companies at the intersection of science, technology, and industry. The firm backs ventures applying research across sectors including artificial intelligence, biotechnology, advanced materials, space, and energy, with an emphasis on translating complex innovations into scalable businesses. Lux provides capital together with strategic input on product development, company building, and long-term positioning, and takes an active role to help founders navigate technical and market challenges. The firm evaluates opportunities based on the underlying science, potential industry impact, and feasibility of execution over extended horizons. With offices in New York and Silicon Valley, Lux collaborates with technical founders, researchers, and teams to build durable market leaders and accelerate scientific breakthroughs into real-world applications.

Kurma Partners is a Paris-based investment firm focused on financing innovation in healthcare and biotechnology across Europe. It manages multiple funds, including early-stage life sciences funds, to support therapeutic and medical innovations from early concept to development, with active collaboration with academic research institutes and hospitals. The firm emphasizes a collaborative, hands-on approach, providing capital and strategic guidance to portfolio companies, often forming strong partnerships with research teams to translate scientific discoveries into medicines and medical devices. Kurma Partners targets investments in life sciences, pharmaceuticals, biotechnology, digital health and related technology sectors, and pursues opportunities across Europe, integrating ESG practices into its investment processes.

Northpond Ventures is a science-driven venture capital firm headquartered in Bethesda, Maryland, with offices in San Francisco, California, and Cambridge, Massachusetts. Founded in 2018, the firm concentrates on life sciences, digital health and health tech, and related technologies, including diagnostics, therapeutics, artificial intelligence and machine learning. It seeks to back companies translating scientific advances into practical solutions with significant societal impact, combining rigorous scientific assessment with strategic partnerships to support research, development and commercialization.

Deep Track Capital is a biotechnology investment firm based in Greenwich, Connecticut. It focuses on the life sciences and biotech sector, forging partnerships with management teams of innovative public and pre-IPO biotechnology companies, and aims to invest time, expertise, and its network alongside capital to support partners. The firm seeks to lead transactions while forming large syndicates and to participate in rounds led by other qualified investors.

Section 32 is a California-based venture capital firm founded in 2017 and headquartered in Silicon Valley. It concentrates on early‑stage technology, software, data, AI, enterprise software, cybersecurity, quantum computing, computational biology, biotechnology, life sciences, and healthcare companies across the United States. Founded by Bill Maris, the firm pursues a capital‑constrained, hands‑on investment approach, reserving substantial resources for a small number of companies and offering active support in areas such as talent acquisition and execution. Section 32 seeks founders building iconic, frontier‑level technology companies that can broadly improve the human condition.

Takeda Pharmaceutical is a global biopharmaceutical leader and Japan’s largest pharmaceutical company. It researches, develops, manufactures, and markets prescription medicines and vaccines across oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies. The company serves patients worldwide with a diversified geographic footprint—roughly half of revenue from the United States, about 10% from Japan, 25% from Europe, and 15% from Canada. Takeda emphasizes patient-centered growth, sustainability, and ethical practices, supported by a strong focus on research and development to translate science into transformative medicines.

DCVC is a deep-tech venture capital firm based in Palo Alto, California, with activities in San Francisco, that funds companies applying advanced science and engineering to major global challenges. The firm backs early- and growth-stage startups across artificial intelligence, exascale computing, climate tech, engineering, materials science, robotics, space, water, biology, defense, security, and other deep-tech sectors, and maintains specialized units such as DCVC Bio focused on life sciences. DCVC emphasizes scientifically rigorous teams and data-driven approaches, collaborating with researchers and entrepreneurs to accelerate development through AI, automation, and data-centric methods. It operates as a registered investment adviser and supports ambitious founders developing transformative technologies across software, big data, healthcare, and energy.

TCG Crossover is a science-driven healthcare investment firm focused on identifying and advancing disruptive medicines. The firm invests in private and public biotechnology and health-technology companies led by entrepreneurs pursuing innovative treatments, with investment teams based in Palo Alto and New York City. Its approach emphasizes supporting ventures that aim to improve patient outcomes and accelerate pharmaceutical development through a research-driven portfolio and strategic backing.

Boxer Capital is the corporate venture capital arm of Tavistock Group that concentrates its investments in biotechnology and life sciences. Based in San Diego, California, the firm pursues opportunities in both private and public biotechnology companies across the entire drug development lifecycle, from early discovery assets to late-stage clinical and commercial programs. It combines scientific expertise with investment experience to evaluate targets across therapeutic areas, emphasizes precision medicine, and seeks to support transformative medical advances through disciplined, research-driven analysis and active partnerships with portfolio companies.

Third Rock Ventures is a Boston-based venture capital firm focused on early-stage life sciences and healthcare companies. Founded in 2007, it targets companies developing therapies, diagnostics, devices, and related technologies that address unmet medical needs. The firm seeks meaningful, high-growth opportunities in the United States, often leading initial investments and engaging actively in portfolio companies, sometimes taking management roles or forming strategic collaborations with larger pharmaceutical and biotechnology partners. Third Rock emphasizes hands-on involvement and strategic support to accelerate product development and market progress, with a history of funding companies across oncology, cardiovascular, immunology, gene therapy, and other therapeutic areas. The firm operates through multiple venture funds and maintains a focus on Boston, with additional presence in San Francisco, and aims to foster patient-centric, transformative medicines and technologies.

Andreessen Horowitz is a Menlo Park, California-based venture capital firm founded in 2009 by Marc Andreessen and Ben Horowitz. It funds technology startups across seed to late stages, with investments spanning software, cloud infrastructure, enterprise software and services, consumer internet, fintech, artificial intelligence, crypto, infrastructure, and biotechnology at the intersection of computer science and life sciences. The firm emphasizes supporting portfolio companies through growth and strategic partnerships and maintains a broad tech-focused investment approach, aiming to add value beyond capital.

Digitalis Ventures is a New York-based venture capital firm founded in 2016 that concentrates on health-related technology and solutions for both human and animal health. It invests across all stages and across the full healthcare ecosystem, focusing on biotechnology and technology-driven health enterprises. The firm partners with entrepreneurs, inventors, and scientists to finance, build, and scale ventures that address unmet medical needs, improve access to care, enhance outcomes, and reduce costs. In addition to capital, Digitalis leverages technical, financial, and domain expertise to support portfolio companies, and it emphasizes thoughtful analysis and knowledge sharing through regular newsletters such as Notes on Engineering Health and Notes on Animal Health. Digitalis maintains regional offices in Boston, Los Angeles, and San Francisco, in addition to its headquarters in New York City, reflecting an active presence across the United States.

KdT Ventures is an early-stage venture capital firm founded in 2017 and based in Austin, Texas. It focuses on frontier science and related sectors, backing startups innovating across medicine, chemicals, materials, biology, chemistry, physics, and computation. The firm often acts as an initial institutional check in pre-seed and seed rounds, supporting companies that commercialize scientific breakthroughs to reshape how the physical world works. With deep technical expertise and an emphasis on long-term founder relationships, KdT Ventures aims to help portfolio companies develop platforms that engineer matter, energy, and information.

Regeneron Ventures is the corporate venture capital arm of Regeneron Pharmaceuticals, based in Greenwich, Connecticut. It invests in early-stage and emerging biotechnology companies, focusing on novel therapeutic platforms, drug discovery technologies, and breakthrough biomedical innovations across areas such as oncology, immunology, genetics, and precision medicine. The firm supports seed and growth-stage investments and often collaborates with other investors and industry partners to accelerate scientific progress, aiming to translate research into therapies and health technologies that align with Regeneron's biotechnology ecosystem.

Mission BioCapital is a life science venture capital firm focused on early-stage investments in biotechnology and related life sciences in the United States, with offices in Cambridge, Massachusetts and San Francisco. The leadership team has a long history of launching dozens of early-stage life science companies and a track record of providing deep expertise and support to portfolio companies. The firm emphasizes mentorship, collaboration, and founder-centric value creation, and offers programs such as the Platinum Program, which provides up to $500,000 in funding along with lab space and services including drug discovery, legal and financial assistance to accelerate development.

LYFE Capital is a global, pure-play healthcare investment platform that connects healthcare companies with global markets, supply chains, and strategic partners. It has about $2 billion in assets under management and operates five offices across North America and Asia, including Menlo Park, Singapore, Seoul, Tokyo, and Shanghai. The firm invests in healthcare assets, including medical devices, therapeutics, diagnostics, and related platforms and R&D services, to drive growth and value creation for portfolio companies.

Morningside Group is a venture capital firm founded in 1986, originally established as a family office for the Chan family, and is based in the greater Boston area. The firm makes venture investments in companies with novel science and technology, pursuing a long-term, patient approach to company-building and emphasizing ethical practices. Its investment focus spans life sciences, digital health, artificial intelligence, materials science, and information technology. In addition to its investment activities, Morningside supports charitable initiatives in education, research, and healthcare, with partnerships including the Harvard T.H. Chan School of Public Health, UMass Chan Medical School, and the MIT Morningside Academy for Design.

Kleiner Perkins is an American venture capital firm founded in 1972 and based in Menlo Park, California. It specializes in early-stage, growth, and incubation investments, partnering with founders from inception to IPO and beyond. The firm backs entrepreneurs across a broad range of sectors, including technology, digital media, life sciences, healthcare, consumer products and services, software, cybersecurity, and infrastructure, providing strategic guidance and networks to help companies scale and create long-term value.

Civilization Ventures is a venture capital firm focused on early-stage health technology and biology companies. It targets opportunities in digital health, diagnostics, synthetic biology, genomics, 3D bioprinting, gene therapies, and AI-enabled health tech, aiming to be the first check and lead investor for disruptive startups. The team comprises serial entrepreneurs and industry thought leaders who actively support portfolio companies through growth. Founded in 2017 with a pilot fund, Civilization Ventures has grown to manage over $200 million and has invested in more than 70 companies, with 17 exits, including three unicorns. The firm runs a fellowship program that trains PhDs to become entrepreneurs and leverages a biopharma executive network to assist founders through seed, pre-seed, and scaling rounds.

Alumni Ventures is a venture capital firm based in Manchester, New Hampshire, with offices in New York, Boston, Menlo Park, Chicago, London, and Tokyo. It enables accredited investors, especially alumni networks, to access diversified venture opportunities by co-investing alongside leading venture capital firms. Through funds, syndicates, and investing clubs, it sources opportunities across stages and geographies, conducts rigorous due diligence, and aims for transparent, founder-friendly support. The firm backs a diversified portfolio of startups, including more than 1,600 companies, and has attracted substantial committed capital and a large community of individual investors, underscoring its mission to democratize access to venture capital while partnering with established VC firms.

Omega Funds is a Boston, Massachusetts-based venture capital firm focused on life sciences and healthcare investments across North America and Western Europe. The firm targets opportunities in the life sciences, digital health, immunology, rare diseases, precision medicine, oncology, cybersecurity, and software-as-a-service, leveraging an experienced team and broad network to support entrepreneurs and founders. It has facilitated the development of products reaching patients and has a track record that includes a public listing and an M&A deal. The firm operates across multiple funds and engages with the European ecosystem, sharing insights through publications such as the Omega Insights Series.

EcoR1 Capital is a biotechnology-focused venture capital firm based in San Francisco. The firm seeks to invest in biotech companies and drug discovery programs, aiming to support scientific breakthroughs and develop new medicines. It pursues long-term partnerships with ambitious entrepreneurs and favors a collaborative approach that leverages curiosity and a deep understanding of molecular mechanisms to identify and realize opportunities in biology and chemistry. As a registered investment adviser, EcoR1 Capital positions itself to back innovative therapies addressing unmet medical needs and to contribute to advances that improve patients' lives.

Sofinnova Investments is a venture capital firm founded in 1976 and headquartered in Menlo Park, California, with offices in La Jolla, Montreal and Tokyo. It backs life sciences and information technology companies across the United States and Europe, from seed through early and growth stages. In life sciences, it targets clinical-stage pharmaceutical and biotechnology companies, drug discovery platforms, and medical technology addressing diseases with unmet medical needs, including oncology, respiratory, dermatology, ophthalmology, neurology and women's health. In information technology, it supports product-oriented software, enterprise IT solutions and telecommunications infrastructure. The firm often requires board participation for early-stage lead or co-lead investments and emphasizes hands-on guidance to help entrepreneurs build global businesses.

SR One is the corporate venture capital arm of GlaxoSmithKline, a trans-Atlantic biotechnology investor focused on funding innovative science to develop new medicines. It operates from biotechnology hubs on the West Coast and in London, leveraging its cross-Atlantic presence to provide strategic partnerships, geographic reach, and portfolio support that accelerates the translation of scientific breakthroughs into medicines. Founded in 1985, SR One has invested about 800 million dollars in more than 180 life science companies, and it employs a back-and-build approach that prioritizes strong scientific fundamentals, clear development plans, and novel approaches to disease treatment.

Legend Capital is a Beijing-based venture capital firm founded in 2001 and affiliated with Legend Holdings. It focuses on early-stage venture capital and growth equity investments in China and markets related to China, aiming to back high-growth technology-enabled companies and cross-sector ventures. The firm concentrates on sectors such as information technology, communications, consumer, healthcare, industrials, and modern services, with an emphasis on companies that leverage China's scale and ecosystem. Legend Capital provides portfolio companies with strategic resources, network access, and operational support to accelerate business development in the Chinese market and beyond. Over the years, it has built a substantial portfolio of companies and exited a number of investments through various channels, reflecting its role in supporting entrepreneurship and ecosystem development in China's venture capital landscape. The firm operates from offices in major Chinese cities and Hong Kong to support entrepreneurs and partners across the region.

MPM Capital is a Cambridge-headquartered healthcare investment firm that funds biotechnology, oncology, and life sciences companies. It invests across the company lifecycle, from seed and early development to growth and late-stage programs, aiming to translate scientific advances into clinical outcomes. The firm backs ventures in medical technology, oncology, specialty pharma, and medical devices and pursues global opportunities in the United States, Europe, and Asia, with a focus on India. Founded in 1996, MPM Capital collaborates with researchers, clinicians, and entrepreneurs to support portfolio companies through development milestones and proof-of-concept data.

The Dementia Discovery Fund is a global venture capital initiative focused on financing companies developing novel therapeutics and enabling technologies for dementia. It leverages a broad network of venture partners, scientists, entrepreneurs, and strategic collaborators to identify, fund, and develop biotech ventures that advance dementia research and treatment. With offices in London and Boston, the initiative mobilizes capital and expertise to accelerate scientific progress and seeks meaningful patient impact alongside financial returns. It is supported by a diverse base of partners from the pharmaceutical industry and philanthropic organizations.